Venture Capital Fundraising in Healthcare Remains Healthy; Silicon Valley Bank Releases 15th Edition of Healthcare Investments and Exits Report

About this update from First Citizens Bancshares, Inc.

[{"type":"text","content":"New report finds $5.6 billion invested in biopharma AI in 2024\nSAN FRANCISCO, Jan. 8, 2025 /PRNewswire/ -- Venture Capital (VC) investment in healthcare grew to $23 billion in 2024, from $20 billion in 2023, as artificial intelligence (AI) clearly established product fit in the healthcare sector, according to the latest market insights report from Silicon Valley Bank (SVB), a division of First Citizens Bank. AI continues to take center stage, especially across biopharma, with 30% of healthcare investment in 2024 going to companies leveraging AI.\n\n \n \n \n \n \n \n\n \nWith more than $5 billion in 2024, investment in biopharma AI was the story of the year. The sector saw a 300% increase in investment since 2023, surging past 2021 total capital invested by nearly $2 billion. Investment was largely driven by mega deals, with deals over $100 million accounting for 71% of total 2024 investment in biopharma AI, according to the report.\n\"In 2025, we could see a steady yet modest increase in both the volume and value of investments across various healthcare sectors,\" said Jackie Spencer, Head of Relationship Management for Life Science and Healthcare Banking at Silicon Valley Bank and author of the annual Healthcare Investments and Exits Report. \"However, despite this growth, IPO activity is likely to remain subdued as market conditions continue to stabilize and investors remain cautious. Advancements in AI are poised to revolutionize drug development and clinical trial management, driving efficiencies, precision, and speed in bringing new therapies to market.\"\nSVB's 2025 Healthcare Investment and Exits report analyzes and predicts trends for venture capital investing, fundraising, and exits across healthtech, biopharma, diagnostics/tools (dx/tools), and device sectors in the US.\nKey report findings:\nSeed Rounds: Seed rounds rose to 40% of all deals as investors look forward. Among all companies receiving a seed deal in 2024, 35% are leveraging AI – up from 25% in 2023.Biopharma: With AI-driven protein design gaining momentum and results from clinical trials for AI-designed drugs on the way, excitement for biopharma AI is expected to remain high.Valuations: Valuations saw a 1.5x median increase among companies raising after a down round.Healthtech: With notable raises going to companies with proven track records and strong h...

More updates from First Citizens Bancshares, Inc.